Insider · CIK 0001734755
Michael Vasconcelles
officerdirector
Files at KURA (Kura Oncology, Inc.), DAWN (Day One Biopharmaceuticals, Inc.). First filing Feb 18, 2026, latest Feb 18, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $32k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Day One Biopharmaceuticals, Inc. | $32k 2,728 shares | -38% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +7,125 | - | - | 7,125 | Feb 18, 2026 |
| Feb 17, 2026 | DAWN Day One Biopharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,728 | $11.60 | $32k | 4,397 | Feb 18, 2026 |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -7,125 | $0.00 | $0 | 106,875 | Feb 18, 2026 |
| Jan 30, 2026 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Stock Option (right to buy Common Stock)derivative | +171,000 | $0.00 | $0 | 171,000 | Jan 30, 2026 |
| Jan 30, 2026 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +114,000 | $0.00 | $0 | 114,000 | Jan 30, 2026 |
| Jun 16, 2025 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Stock Option (right to buy Common Stock)derivative | +346,000 | $0.00 | $0 | 346,000 | Jun 18, 2025 |
| Jun 16, 2025 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Restricted Stock Unit (RSU)derivative | +226,000 | $0.00 | $0 | 226,000 | Jun 18, 2025 |
| Jun 5, 2025 | KURA Kura Oncology, Inc. | AGrant or award Option to purchase common stockderivative | +28,500 | $0.00 | $0 | 28,500 | Jun 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.